BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 19570512)

  • 1. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
    Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
    Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
    Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
    Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 8. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
    Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
    Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Cadherin and Tie2 positive CD34⁺CD38⁻CD123⁺ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice.
    Qiu S; Jia Y; Xing H; Yu T; Yu J; Yu P; Tang K; Tian Z; Wang H; Mi Y; Rao Q; Wang M; Wang J
    Leuk Res; 2014 May; 38(5):632-7. PubMed ID: 24703771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
    Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
    Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
    Majeti R
    Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.
    Lee JY; Park S; Han AR; Lim J; Min WS; Kim HJ
    Oncol Rep; 2014 Oct; 32(4):1638-46. PubMed ID: 25069538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.